Related Experiment Video

Updated: May 8, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Targeting EGFR and PI3K pathways in ovarian cancer

S Glaysher1, L M Bolton, P Johnson

  • 1Translational Oncology Research Centre, Queen Alexandra Hospital, Portsmouth PO6 3LY, UK.

British Journal of Cancer
|September 12, 2013
PubMed
Abstract

Insights

Combining PI3K inhibitors with EGFR inhibitors shows promise for ovarian cancer treatment, offering enhanced activity and potential synergy. Further clinical trials are recommended to identify patient subgroups who will benefit most from this targeted therapy approach.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) is present in ovarian cancer but single-agent therapies show limited efficacy.
  • Alternative pathways, such as the PI3K/Akt/MTOR pathway, may contribute to treatment resistance.
  • Investigating combined inhibition of EGFR and PI3K pathways is crucial for improving ovarian cancer treatment.

Purpose of the Study:

  • To evaluate the efficacy of combining PI3K inhibitors (ZSTK474, sirolimus) with EGFR inhibitors (erlotinib, gefitinib) in ovarian cancer.
  • To explore potential synergistic effects and identify biomarkers predictive of response.

Main Methods:

  • Primary ovarian cancer cell cultures were treated with single agents and drug combinations.
  • Assays were performed to assess drug activity, synergy, and potential resistance mechanisms.
  • Tumor molecular profiling (e.g., PIK3CA, PTEN, KRAS) was conducted.

Main Results:

  • Single-agent EGFR inhibitors had minimal activity; ZSTK474 showed some single-agent activity.
  • Combinations of ZSTK474 with EGFR inhibitors demonstrated enhanced activity and synergy.
  • Sirolimus combinations were less effective. EGFR expression correlated with sensitivity to EGFR inhibitors and resistance to PI3K agents.

Conclusions:

  • Combined inhibition of EGFR and PI3K pathways shows therapeutic potential in ovarian cancer.
  • Further clinical trials (Phase I/II) are warranted with detailed pharmacodynamic and molecular analyses.
  • Identifying predictive biomarkers is essential for patient stratification and optimizing treatment strategies.

More Related Videos

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...